Circulating soluble cytochrome <i>c</i> in liver disease as a marker of apoptosis

Ben‐Ari, Ziv; Schmilovotz‐Weiss, H.; Belinki, A.; Pappo, Orit; Sulkes, Jaqueline; Neuman, Manuela G.; Kaganovsky, Ella; Kfir, B.; Tur–Kaspa, Ran; Klein, Tirza

doi:10.1046/j.1365-2796.2003.01171.x

Cited by 35 publications

(41 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have shown that cytochrome c release outside the cell occurs without concomitant release of larger molecules, such as lactate dehydrogenase, which is considered a marker of cell necrosis, with disruption of the cell membrane (1,6,7,37). Regardless of the mechanisms, our study demonstrated a progressive rise in plasma cytochrome c during the postresuscitation period to levels that were inversely related to survival outcome.…”

Section: Cytochrome C Release To the Bloodstreamsupporting

confidence: 48%

Circulating levels of cytochromecafter resuscitation from cardiac arrest: a marker of mitochondrial injury and predictor of survival

Radhakrishnan

Wang²,

Ayoub³

et al. 2007

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

show abstract

Section: Cytochrome C Release To the Bloodstreamsupporting

confidence: 48%

Circulating levels of cytochromecafter resuscitation from cardiac arrest: a marker of mitochondrial injury and predictor of survival

Radhakrishnan

Wang²,

Ayoub³

et al. 2007

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

show abstract

“…Ahlemeyer and colleagues similarly found that cytochrome c is released extracellularly after staurosporine-induced apoptosis, and suggested that extracellular cytochrome c may contribute to neuronal apoptosis (Ahlemeyer et al, 2002). Several studies have since been undertaken using the serum cytochrome c level as a marker of apoptosis (Adachi et al, 2004;Barczyk et al, 2005;Ben-Ari et al, 2003). Our data suggest that peak CSF cytochrome c levels may reflect the degree of apoptosis after TBI, possibly resulting in worse brain injury and ultimately poor outcome.…”

supporting

confidence: 53%

Cerebrospinal Fluid Levels of High-Mobility Group Box 1 and Cytochrome C Predict Outcome after Pediatric Traumatic Brain Injury

Aneja

Bell

et al. 2012

Journal of Neurotrauma

View full text Add to dashboard Cite

High-mobility group box 1 (HMGB1) is a ubiquitous nuclear protein that is passively released from damaged and necrotic cells, and actively released from immune cells. In contrast, cytochrome c is released from mitochondria in apoptotic cells, and is considered a reliable biomarker of apoptosis. Thus, HMGB1 and cytochrome c may in part reflect the degree of necrosis and apoptosis present after traumatic brain injury (TBI), where both are felt to contribute to cell death and neurological morbidity. Ventricular cerebrospinal fluid (CSF) was obtained from children admitted to the intensive care unit (ICU) after TBI (n = 37). CSF levels of HMGB1 and cytochrome c were determined at four time intervals (0-24 h, 25-48 h, 49-72 h, and > 72 h after injury) using enzyme-linked immunosorbent assay (ELISA). Lumbar CSF from children without TBI served as controls (n = 12). CSF HMGB1 levels were: control = 1.78 -0. In conclusion, increased CSF levels of HMGB1 and cytochrome c were associated with poor outcome after TBI in infants and children. These data are also consistent with the designation of HMGB1 as a ''danger signal.'' Distinctly increased CSF cytochrome c levels in infants and children with AHT and poor outcome suggests that apoptosis may play an important role in this unique patient population.

show abstract

“…A strong correlation between the clinical symptoms of fulminant liver damage and serum cytochrome c level has been described (Ben-Ari et al, 2003;Ghavami et al, 2005;Sakaida et al, 2005). The serum cytochrome c level also seemed to parallel the severity of hepatic coma (Sakaida et al, 2005).…”

Section: A U T H O R ' S P E R S O N a L C O P Ymentioning

confidence: 90%

“…The extracellular cytochrome c release appears to be specific for apoptosis (Renz et al, 2001a), and its presence can easily be detected in body fluids including serum (Barczyk et al, 2005;Ben-Ari et al, 2003;Kawada et al, 2006;Renz et al, 2001a), and cerebro-spinal fluid (Satchell et al, 2005) ( Table 1). In cancer patients, increased levels of cytochrome c in the serum correlate with the onset of in vivo-ongoing cell death induced by cancer therapy (Barczyk et al, 2005;Renz et al, 2001a), and preliminary results indicate that it correlates with long-term survival (Barczyk et al, 2005).…”

Section: A U T H O R ' S P E R S O N a L C O P Ymentioning

confidence: 99%

“…The serum cytochrome c level also seemed to parallel the severity of hepatic coma (Sakaida et al, 2005). In patients suffering from fulminant hepatitis, the serum cytochrome c level significantly correlated to serum hepatocyte growth factor, aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and alkaline phosphatase (ALP), while it was negatively correlated to serum alpha-fetoprotein (AFP) and total plasma bilirubin (Ben-Ari et al, 2003;Sakaida et al, 2005).…”

Section: A U T H O R ' S P E R S O N a L C O P Ymentioning

confidence: 99%

See 1 more Smart Citation

Methods and biomarkers for the diagnosis and prognosis of cancer and other diseases: Towards personalized medicine

Anderson

Hansen

Mooren

et al. 2006

Drug Resistance Updates

View full text Add to dashboard Cite

The rapid development of new diagnostic procedures, the mapping of the human genome, progress in mapping genetic polymorphisms, and recent advances in nucleic acid-and protein chip technologies are driving the development of personalized therapies. This breakthrough in medicine is expected to be achieved largely due to the implementation of "lab-on-the-chip" technology capable of performing hundreds, even thousands of biochemical, cellular and genetic tests on a single sample of blood or other body fluid. Focusing on a few disease-specific examples, this review discusses selected technologies and their combinations likely to be incorporated in the "lab-on-the-chip" and to provide rapid and versatile information about specific diseases entities. Focusing on breast cancer and after an overview of single-nucleotide polymorphism (SNP)-screening methodologies, we discuss the diagnostic and prognostic importance of SNPs. Next, using Duchenne muscular dystrophy (DMD) as an example, we provide a brief overview of powerful and innovative integration of traditional immuno-histochemistry techniques with advanced biophysical methods such as NMR-spectroscopy or Fourier-transformed infrared (FT-IR) spectroscopy. A brief overview of the challenges and opportunities provided by protein and aptamer microarrays follows. We conclude by highlighting novel and promising biochemical markers for the development of personalized treatment of cancer and other diseases: serum cytochrome c, cytokeratin-18 and -19 and their proteolytic fragments for the detection and quantitation of malignant tumor mass, tumor cell turn-over, inflammatory processes during hepatitis and Epstein-Barr virus (EBV)-induced hemophagocytic lymphohistiocytosis and apoptotic/necrotic cancer cell death.

show abstract

Circulating soluble cytochrome c in liver disease as a marker of apoptosis

Cited by 35 publications

References 38 publications

Circulating levels of cytochromecafter resuscitation from cardiac arrest: a marker of mitochondrial injury and predictor of survival

Circulating levels of cytochromecafter resuscitation from cardiac arrest: a marker of mitochondrial injury and predictor of survival

Cerebrospinal Fluid Levels of High-Mobility Group Box 1 and Cytochrome C Predict Outcome after Pediatric Traumatic Brain Injury

Methods and biomarkers for the diagnosis and prognosis of cancer and other diseases: Towards personalized medicine

Contact Info

Product

Resources

About